Nature Reviews Drug Discovery 12, 829–846 (2013)
There were some inaccuracies in the following sentence on p839 of the article: “Along similar lines, the pharmacological or genetic inhibition of phosphoglycerate mutase 1 (PGAM1) reduces tumour growth in vitro and in vivo, perhaps owing (at least in part) to the G6PD-inhibitory effects of 3-phosphoglycerate222. That said, genetic defects that have an impact on the enzymatic activity of G6PD are common among individuals living in geographical areas with a history of endemic malaria223.”
The correct sentence is as follows: “Along similar lines, the pharmacological or genetic inhibition of phosphoglycerate mutase 1 (PGAM1) reduces tumour growth in vitro and in vivo, perhaps owing (at least in part) to the PPP-inhibitory effects of 3-phosphoglycerate222. That said, genetic defects that have an impact on the enzymatic activity of G6PD (and hence inhibit the PPP) are common among individuals living in geographical areas with a history of endemic malaria223.”
This has now been corrected in the online version of the article.
Additional information
The online version of the original article can be found at 10.1038/nrd4145
Rights and permissions
About this article
Cite this article
Galluzzi, L., Kepp, O., Heiden, M. et al. Erratum: Metabolic targets for cancer therapy. Nat Rev Drug Discov 12, 963 (2013). https://doi.org/10.1038/nrd4191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4191
